Tees, Esk and Wear Valleys NHS Foundation Trust

PRESCRIBING GUIDELINES FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN & YOUNG PEOPLE

Complete baseline ADHD assessment & offer medication to children aged 5 years and over* and young people if:

- Their ADHD symptoms are still causing persistent, significant impairment in at least one domain after environmental modifications have been implemented and reviewed
- They and their parents/carers have discussed information about ADHD

For pre-treatment assessment & ongoing monitoring click here & print patient information leaflets from Choice and medication website

* N/B drug treatments not licensed in children under 6 years

Prescribe methylphenidate immediate release, Or Prescribe a methylphenidate modified release preparation for: convenience, increased adherence, reduced stigma at school or better pharmacokinetics (see overleaf for options) Start at the appropriate dose using the current BNFC & increase dose as appropriate to the minimum effective dose. If 6 week trial at an adequate dose and not Effective management of symptoms derived enough benefit in terms of reduced with minimal side effects - continue ADHD symptoms and associated with minimum effective dose and impairments - stop methylphenidate transfer prescribing to primary care in line with shared care guidelines Prescribe lisdexamfetamine² at the recommended dose in the current BNFC. Review at least annually once stable Switch to dexamfetamine if responds to If ineffective treatment (not responded to 6 lisdexamfetamine but week trial of adequate doses) or intolerable can't tolerate longer side effects, having considered alternative effect profile preparations - stop lisdexamfetamine (dexamfetamine) \mathbf{V} Consider adjunctive therapies only with Prescribe atomoxetine at the recommended dose in advice from tertiary service: e.g. atypical the current BNFC. If effective, review every at least antipsychotics (co-existing pervasive annually or Prescribe guanfacine³ at the appropriate aggression, rages or irritability) or clonidine dose. If effective, assess every 3 months (during first (sleep disturbance, rages or tics) (both year), every 6 months thereafter. unlicensed)1

PRESCRIBING ADVICE FOR ALL PATIENTS

All medication is licensed for children over 6 years unless otherwise stated. Prior to initiation check the <u>BNF</u> or relevant <u>product information</u> for any <u>cautions</u> or <u>contra-indications</u> to the chosen treatment. Review diagnosis and co-morbidities if expected response to treatment is not observed, especially when changing type of drug treatment (stimulant to non-stimulant, and vice versa). Seek second opinion or refer to tertiary services any child or young person unresponsive to one or more stimulants or one non-stimulant.

Consider a drug holiday during school holidays to minimise adverse effects. Consider shared care once nation is

Consider a drug holiday during school holidays to minimise adverse effects. Consider shared care once patient is clinically stable.

- 1. For advice on appropriate dosages or conversion, please contact a member of the Trust pharmacy team
- 2. Capsules may be opened and the capsule contents sprinkled onto a small amount (tablespoon) of apple sauce or yoghurt and given immediately, and not stored for future use.
- 3. Consider guanfacine before atomoxetine & other stimulants (i.e. 2nd line) in children who lose significant weight on methylphenidate

Title	Prescribing Guidelines for ADHD in Children & Young People				
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, amended 24/11/22		
Protocol Number	PHARM-0077-v3.1	Date of Review	1 st June 2025 (extended)		



PRESCRIBING GUIDELINES FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN & YOUNG PEOPLE

AVAILABLE METHYLPHENIDATE MODIFIED-RELEASE PREPARATIONS (see guidance <u>here</u> for more information on relative pharmacokinetics)

Brand	Available strengths	Description	Release profile	NHS indicative price (30)	Brand	Available strengths	Description	Release profile	NHS indicative price (30)
Preparations with 22% immediate-release component and 78% extended-release components				Preparations with 30% immediate-release component and 70% extended-release component					
Delmosart tablets	18 mg	Yellow capsule shape tablet		£15.57	Equasym XL capsules ²	10 mg	Dark green opaque capsule	Immediate-release component gives a maximum plasma	£25.00
	27 mg	Grey capsule shape tablet		£18.39		20 mg	Blue opaque capsule	concentration after 1.5 hours; extended-release component	£30.00
	36 mg	White capsule shape tablet		£21.23		30 mg	Reddish brown opaque capsule	gives a second peak after 6 hours. Duration of action up to 8 hours.	£35.00
	54 mg	Red capsule shape tablet		£36.79	Preparations with 50% immediate-release component and 50% extended-release component				
Xenidate XL	18 mg	Yellow round tablet		£15.57	Medikinet XL	5 mg	White capsule	Immediate-release component	£24.04
tablets	27 mg	Yellow oblong tablet		£18.39	capsules ²	10 mg	Lilac/ white capsule	gives a rapid peak plasma	£24.04
	36 mg	White oblong tablet		£21.21	Take with or	20 mg	Lilac capsule	concentration; extended-	£28.86
	54 mg	Red oblong tablet	Immediate-release component gives a maximum plasma	£36.79	after breakfast	30 mg	Purple/ light grey capsule	release component gives a second peak after 3-4 hours.	£33.66
Xaggitin XL tablets	18 mg	Yellow capsule shape tablet	concentration after 1-2 hours; extended-release component	£15.58		40 mg	Purple/ grey capsule	Duration of action up to 8 hours.	£57.72
	27 mg	Grey capsule shape tablet	gives a second peak after 6-8 hours.	£18.40		50 mg	Violet/dark violet capsule		£62.52
	36 mg	White capsule shape tablet	Duration of action up to 12 hours.	£21.22		60 mg	Dark violet capsule		£67.32
	54 mg	Red/brown capsule shape tablet		£36.80	Ritalin XL capsules ²	10 mg	Brown opaque capsule	Immediate-release component gives a rapid peak plasma	£23.92
Concerta XL tablets	18 mg	Yellow capsule shape tablet		£31.19	Can be taken with or without	20 mg	White opaque capsule	concentration at 1-2 hours; extended-release component	£28.72
	27 mg	Grey capsule shape tablet		£36.81	food	30 mg	Yellow opaque capsule	gives a second peak after 4 hours.	£33.49
	36 mg	White capsule shape tablet		£42.45		40 mg	Brown opaque capsule	Duration of action up to 8 hours.	£57.43
	54 mg	Red capsule shape tablet		£73.62		60 mg	Brown and yellow opaque capsule		£66.98
Matoride XL	18 mg	Yellow round tablet]	£15.58					
tablets	36 mg	White round tablet		£21.22					
	54 mg	Pink round tablet		£36.80					

Title	Prescribing Guidelines for ADHD in Children & Young People				
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, amended 24/11/22		
Protocol Number	PHARM-0077-v3.1	Date of Review	1 st June 2025 (extended)		